LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed advanced adenocarcinoma of the colon, rectum, pancreas, esophagus, or stomach that is refractory to standard treatment
• Overexpression of the Lewis-Y antigen
• Measurable or evaluable disease
• No CNS metastasis
• Metastatic liver disease from primary tumor allowed
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-1
• Life expectancy:
• At least 3 months
• Hematopoietic:
• Platelet count greater than 100,000/mm\^3
• Absolute granulocyte count greater than 1,200/mm\^3
• Hepatic:
• Bilirubin normal
• SGOT and SGPT no greater than 1.5 times upper limit of normal
• Hepatitis B or C antigen negative
• No liver disease (e.g., alcohol liver disease)
• Albumin at least 3.0 g/dL
• Renal:
• Creatinine no greater than 1.4 mg/dL
• Creatinine clearance at least 60 mL/min
• Proteinuria no greater than 1 g/24 hours (grade II toxicity-like)
• Cardiovascular:
• No prior coronary artery disease
• No New York Heart Association class II, III, or IV congestive heart failure
• No arrhythmia requiring treatment
• Pulmonary:
• FEV\_1 and FVC greater than 65% predicted
• Other:
• No other concurrent malignancy
• No active peptic ulcer disease
• No known allergy to omeprazole
• No known seizure disorder
• No concurrent medical or psychiatric condition that would preclude study participation
• No contraindication to pressor therapy
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Endocrine therapy:
• At least 3 weeks since prior hormonal therapy
• Radiotherapy:
• At least 3 weeks since prior radiotherapy and recovered
• Surgery:
• Not specified